Several other brokerages have also issued reports on CBMG. ValuEngine lowered Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a report on Friday, October 11th. Cantor Fitzgerald started coverage on Cellular Biomedicine Group in a report on Tuesday, June 25th. They issued an “overweight” rating and a $27.00 price target on the stock. Finally, BTIG Research started coverage on Cellular Biomedicine Group in a research note on Tuesday, September 17th. They issued a “buy” rating and a $19.00 price objective for the company. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cellular Biomedicine Group currently has a consensus rating of “Buy” and an average target price of $24.00.
NASDAQ:CBMG traded down $0.13 on Wednesday, hitting $14.80. The stock had a trading volume of 212 shares, compared to its average volume of 29,036. The business’s fifty day moving average is $14.01 and its 200 day moving average is $14.95. The company has a market cap of $293.99 million, a PE ratio of -7.28 and a beta of 2.84. Cellular Biomedicine Group has a 52 week low of $10.98 and a 52 week high of $20.63.
Several institutional investors have recently modified their holdings of CBMG. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Cellular Biomedicine Group by 38.0% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 528,418 shares of the biotechnology company’s stock valued at $8,735,000 after acquiring an additional 145,616 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its stake in Cellular Biomedicine Group by 37.0% during the second quarter. Nikko Asset Management Americas Inc. now owns 532,318 shares of the biotechnology company’s stock valued at $8,799,000 after buying an additional 143,798 shares during the period. BlackRock Inc. boosted its stake in Cellular Biomedicine Group by 16.0% during the second quarter. BlackRock Inc. now owns 749,694 shares of the biotechnology company’s stock valued at $12,394,000 after buying an additional 103,540 shares during the period. AWM Investment Company Inc. bought a new stake in Cellular Biomedicine Group during the second quarter valued at $1,325,000. Finally, ARK Investment Management LLC lifted its stake in Cellular Biomedicine Group by 10.0% during the second quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock worth $5,197,000 after purchasing an additional 28,616 shares during the last quarter. 20.37% of the stock is owned by hedge funds and other institutional investors.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Read More: Average Daily Trade Volume Explained
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.